Divis Laboratories Ltd Quarterly Results

Q4 FY25-26 Results Summary

Revenue

The revenue stands at ₹2,831.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 8.72 per cent from ₹2,604.00 crore. This corresponds to a year-on-year *(YoY) growth of 9.52 per cent.

Operating Profit

Operating Profit stands at ₹934.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 14.46 per cent from ₹816.00 crore. This corresponds to a year-on-year *(YoY) growth of 5.42 per cent.

PBDT

PBDT stands at ₹1,083.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 20.60 per cent from ₹898.00 crore. This corresponds to a year-on-year *(YoY) growth of 11.53 per cent.

Profit Before Tax

Profit Before Tax stands at ₹963.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 23.46 per cent from ₹780.00 crore. This corresponds to a year-on-year *(YoY) growth of 11.46 per cent.

Net Profit

Net Profit stands at ₹751.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 28.82 per cent from ₹583.00 crore. This represents a 13.44 per cent year-on-year *(YoY) growth for the same year.

  • YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.

Divis Laboratories Ltd Earnings

CategoryQ4 FY25-26Q4 FY24-25Change %FY25-26FY24-25Change %
Total Revenue2,831.002,585.009.5210,560.009,360.0012.82
Expenses1,897.001,699.0011.657,193.006,392.0012.53
Other Income155.0086.0080.23507.00352.0044.03
Operating Profit934.00886.005.423,874.003,320.0016.69
Depreciation120.00107.0012.15463.00402.0015.17
Interest6.001.00500.0023.002.001050.00
Profit Before Tax963.00864.0011.463,388.002,916.0016.19
Tax212.00202.004.95868.00799.008.64
Net Profit751.00662.0013.442,568.002,191.0017.21
CategoryQ4 FY25-26Q3 FY25-26Change %
Total Revenue2,831.002,604.008.72
Expenses1,897.001,788.006.10
Other Income155.0088.0076.14
Operating Profit934.00816.0014.46
Depreciation120.00118.001.69
Interest6.006.000.00
Profit Before Tax963.00780.0023.46
Tax212.00197.007.61
Net Profit751.00583.0028.82

Divis Laboratories Ltd Research Reports

ActionTarget Price (₹)BrokerDateReports
Buy 7,375Sharekhan11-Dec-2025
Neutral 6,925Motilal Oswal10-Nov-2025
Neutral 6,320Motilal Oswal07-Aug-2025
Buy 7,225Edelweiss Securities19-May-2025
Neutral 6,200Motilal Oswal04-Feb-2025

Divis Laboratories Ltd Financial Reports

Data not available.

Divis Laboratories Ltd Stock Prices Compare with Peers

Company1 Day1 Week1 Month3 Months6 Month1 Year
Divi's Lab.2.76%8.63%20.71%21.73%35.17%24.08%
Sun Pharma.Inds.-0.88%0.80%6.29%9.06%22.13%21.23%
Torrent Pharma.4.78%1.71%9.44%20.01%27.88%41.23%
Cipla0.61%4.48%1.15%10.35%12.29%-2.80%
Zydus Lifesci.1.14%1.67%2.44%24.94%28.12%17.38%

Divis Laboratories Ltd Corporate Information

Chairman & Independent Directo: Ramesh B V Nimmagadda
Executive Director & MD: Murali K Divi
Executive Director: N V Ramana
Executive Director / Whole Time Director / CEO: Kiran S Divi
ED / WTD - Commercial: Nilima Prasad Divi
Executive Director / Whole Time Director: S. Devendra Rao
Independent Non Exe. Director: S Ganapaty
Independent Non Exe. Director: Sunaina Singh
Independent Non Exe. Director: Kosaraju Veerayya Chowdary
Independent Non Exe. Director: Rajendrakumar Premchand Shah
Company Sec. & Compli. Officer: Satish Choudhury

Divis Laboratories Ltd News

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,

Updated On: 03 Feb 2026 | 9:49 AM IST
More